Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome

British Journal of Haematology

Volumn 154, Issue 1, 2011, Pages 141-143

  D'Alò, Francesco ^a   Leone, Giuseppe ^a   Hohaus, Stefan ^a   Teofili, Luciana ^a   Bozzoli, Valentina ^a   Tisi, Maria Chiara ^a   Rufini, Vittoria ^b   Calcagni, Maria Lucia ^b   Voso, Maria Teresa ^a  

^a Division of Hematology   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Azacytidine; Hodgkin lymphoma; Myelodysplastic syndromes

Indexed keywords

AZACITIDINE; BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CASE REPORT; COMORBIDITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; ERYTHROCYTE TRANSFUSION; HEART ATRIUM FIBRILLATION; HODGKIN DISEASE; HUMAN; LETTER; LYMPH NODE METASTASIS; MALE; MEGALOCYTOSIS; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; THERAPY RELATED MYELODYSPLASTIC SYNDROME; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THYROID CANCER; THYROIDECTOMY;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

EID: 79958826604     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08438.x     Document Type: Letter

References (10)

1. Dickinson, M., Ritchie, D., DeAngelo, D.J., Spencer, A., Ottmann, O.G., Fischer, T., Bhalla, K.N., Liu, A., Parker, K., Scott, J.W., Bishton, M. & Prince, H.M. (2009) Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. British Journal of Haematology, 147, 97-101.
2. Ehlers, A., Oker, E., Bentink, S., Lenze, D., Stein, H. & Hummel, M. (2008) Histone acetylation and DNA demethylation of B cells result in a Hodgkin-like phenotype. Leukemia, 22, 835-841.
3. Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S.D., Seymour, J.F., Bennett, J.M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C., Silverman, L.R. & International Vidaza High-Risk MDS Survival Study Group. (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncology, 10, 223-232.
4. Figueroa, M.E., Skrabanek, L., Li, Y., Jiemjit, A., Fandy, T.E., Paietta, E., Fernandez, H., Tallman, M.S., Greally, J.M., Carraway, H., Licht, J.D., Gore, S.D. & Melnick, A. (2009) MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood, 114, 3448-3458.
5. Greco, M., D'Alò, F., Scardocci, A., Criscuolo, M., Fabiani, E., Guidi, F., Di Ruscio, A., Migliara, G., Pagano, L., Fianchi, L., Chiusolo, P., Hohaus, S., Leone, G. & Voso, M.T. (2010) Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. Blood Cells, Molecules, and Diseases, 45, 181-185.
6. Jiang, Y., Dunbar, A., Gondek, L.P., Mohan, S., Rataul, M., O'Keefe, C., Sekeres, M., Saunthararajah, Y. & Maciejewski, J.P. (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood, 113, 1315-1325.
7. Kantarjian, H., Oki, Y., Garcia-Manero, G., Huang, X., O'Brien, S., Cortes, J., Faderl, S., Bueso-Ramos, C., Ravandi, F., Estrov, Z., Ferrajoli, A., Wierda, W., Shan, J., Davis, J., Giles, F., Saba, H.I. & Issa, J.P. (2007) Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 109, 52-57.
8. Raj, K., John, A., Ho, A., Chronis, C., Khan, S., Samuel, J., Pomplun, S., Thomas, N.S. & Mufti, G.J. (2007) CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia, 21, 1937-1944.
9. Ushmorov, A., Leithäuser, F., Sakk, O., Weinhaüsel, A., Popov, S.W., Möller, P. & Wirth, T. (2006) Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood, 107, 2493-2500.
10. Voso, M.T., Santini, V., Finelli, C., Musto, P., Pogliani, E., Angelucci, E., Fioritoni, G., Alimena, G., Maurillo, L., Cortelezzi, A., Buccisano, F., Gobbi, M., Borin, L., Di Tucci, A., Zini, G., Petti, M.C., Martinelli, G., Fabiani, E., Fazi, P., Vignetti, M., Piciocchi, A., Liso, V., Amadori, S. & Leone, G. (2009) Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clincal Cancer Research, 15, 5002-5007.